Skip to main content
Figure 1 | EJNMMI Research

Figure 1

From: Feasibility and advantage of adding 131I-MIBG to 90Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

Figure 1

Example of discordant131I-MIBG and111In-pentetreotide tumor uptake. SPECT 131I-MIBG (A) and 111In-pentetreotide (B) images and corresponding CT (C) at the same level from subject #6 showing a large metastatic lesion that is both MIBG and pentetreotide positive (thin arrows), along with a metastasis which is MIBG positive and pentetreotide negative (black circle) and another that is pentetreotide positive and MIBG negative (thick arrow).

Back to article page